Chronic Kidney Disease (CKD) is often thought to be a relatively rare condition requiring specialist care. However, early CKD is common and referral of all patients would completely overwhelm existing specialist services. The purpose of this concise guidance is to inform general physicians and general practitioners about the identification and management of CKD, and who to refer for specialist care.
Introduction
Established renal failure (ERF) is uncommon but its treatment with dialysis or transplantation is very expensive. The number of patients receiving renal replacement therapy (RRT) in the UK is rising and is unlikely to reach steady state for another 25 years [1] , costing over 2% of the total NHS budget. These figures make any improvement in the cost-effective treatment of early kidney disease highly desirable.
It is therefore important to note that:
• CKD increases in prevalence exponentially with age; the most common identifiable causes are diabetes and vascular disease. ERF is more common in ethnic minority populations • Late referral of patients with established renal failure requiring renal replacement therapy to specialist renal services is associated with significant extra cost and poor clinical outcomes.
• The great majority of patients starting RRT have progressed from earlier stages of (CKD) and many could have been identified and referred earlier.
• The great majority of patients with early CKD do not progress to ERF but do have increased risks of cardiovascular disease; the risk of death outweighs the risk of progression.
• Progression is associated with proteinuria and uncontrolled hypertension.
• Optimal management of the risk factors for cardiovascular disease also reduces the risk of progression from early CKD to ERF.
Guideline development
This concise guidance is extracted from 'Chronic Kidney Disease in Adults: UK Guidelines for Identification, Management and Referral' [2] . Details of the development process are given in the full guidelines and summarised in Table 1 .
Recommendations were graded using the same system as the National Service Framework for Renal Services (NSF) (see Table 2 ).
• Many of the questions posed by this guidance are about surveillance for, or referral of, kidney disease which have not been addressed by randomised controlled trials and we have had to rely mostly on expert opinion/consensus.
• Recommendations about the diagnosis of kidney disease have been based largely on observational diagnostic accuracy (DA) studies in which the test under consideration is compared with a reference standard; for simplification we have put diagnostic studies as level 3 DA to distinguish them from non-analytic intervention studies, and without subdivision by quality.
• As recommendations on organisation of care, rather than therapy, present problems with grading evidence, many of our recommendations are level 4.
• All recommendations are graded as level 4 evidence unless otherwise stated.
Implementation and cost implications
Disease-specific guidelines pose particular difficulties for implementation when applied to patients with multiple conditions [3] . Many patients with kidney disease have diabetes, hypertension, or cardiovascular disease. For this reason, these guidelines have been developed to be consistent, wherever possible, with existing UK guidelines and are designed to be integrated into the management of cardiovascular risk and diabetes in the NHS.
Full implementation will require:
• Revision of the electronic coding of CKD in the NHS, both in hospital episode statistics and in primary care computer systems.
• Standardisation and simplification of management of CKD.
• Incorporation of markers of quality care of CKD into the Quality and Outcomes Framework and other NHS quality and safety standards.
• Measurement of outcomes such as late referral for dialysis and disparities in access to care.
• Use of the chronic care model [4] , with particular emphasis on decision support systems.
• An educational package for GPs, hospital physicians and surgeons, and community-based nurses, on the recognition and management of CKD.
• Standardisation of creatinine assay methods.
• Full funding of extra laboratory costs.
We have deliberately not addressed the question of which individuals should be responsible for the care plan for CKD outlined here.
• We anticipate that a variety of models will emerge, including conventional shared care between GPs and hospital-based nephrologists; geriatricians, diabetologists, and other secondary care physicians; specialist GPs [5, 6] ; specialist nurses working at General Practice or Primary Care Trust (PCT) level; and computer-based shared care, including systems to prompt clinical actions [7] .
• Disease registers based on primary care IT systems and an adequate IT infrastructure will be an essential pre-requisite for delivery of the care plan for CKD.
• The development of community nephrologists [8] may help to break down unnecessary barriers to the delivery of comprehensive chronic disease management.
Implementation of these guidelines will carry cost implications, particularly for the treatment of patients with anaemia, which is not covered by existing funding. It is important that the NHS develops a clear strategy for equitable funding of the management of CKD. Any system for implementation should be designed to reduce existing ethnic and socioeconomic differences in the consequences of CKD [9] [10] [11] . 
Scope and purpose:
Overall objective of the guidelines
To promote optimal management of patients with CKD within the NHS.
The patient group covered:
Adults with (or at risk of) Chronic Kidney Disease (CKD)
Target audience:
All clinicians, including general physicians, GPs and other health professions who are involved in the management of patients with CKD -in particular those working in diabetes, geriatrics or cardiovascular subspecialties.
Clinical questions covered:
Identification of patients, reduction of risks associated with CKD, and whom to refer to specialist services
Stakeholder involvement:
The Guideline Development Group (GDG):
The Guidelines were instigated by the Renal Association and the RCP Joint Specialty Committee on Renal Disease, in association with: 
Rigour of development
Evidence gathering: Evidence for these guidelines was provided by review of Cochrane Library, and Medline searches by individual members of the group according to their area of expertise. They draw on existing guidance including the relevant NSFs, NICE guidelines, and similar guidelines from other countries.
Review process Drafts were circulated regularly and the group met on 10 occasions Links between evidence and recommendations
The system used to grade the evidence and guidance recommendations is that used by the Renal NSF (see Table 2 ).
Piloting and peer review
The final draft was widely circulated to all relevant parties and their comments incorporated together with the results of pilot exercises on patient referral.
Implementation

Tools for application
Brief summaries are being prepared for use in clinics and surgeries together with versions suitable for electronic booking. Decision support software is being developed.
Plans for review
Review is planned in 4 years Table 2 : Levels of evidence as used in the Renal NSF
Level 1
Meta-analyses, systematic reviews of randomised controlled trials, or randomised controlled trials.
Level 2
Systematic reviews of case-control or cohort studies, or case-control or cohort studies Level 3
Non-analytic studies, e.g. case reports, case series Level 4 Expert opinion (in the absence of any of the above). This includes the views and experiences of people with renal failure and their carers.
Many of the questions posed by this guidance have not been tested by randomised controlled trials and rely on expert evidence. All recommendations are graded level 4 unless stated otherwise. Until laboratories are able to report results in this way, prediction tables can be used to estimate GFR from serum creatinine, age, gender and ethnicity (see Appendix). Alternatively, an on-line GFR calculator based on this equation is available at <http://cgi.www.renal.org/cgi-bin/www.renal.org/eGFR/GFR.pl Table 4 : Criteria for referral to specialist services 
Glomerular fitration rate (GFR)
• Kidney function should be assessed by estimated GFR and CKD is to be classified on this basis (see Table 3 )
 The GFR should be estimated from serum creatinine using the 4- 
Serum Creatinine measurement to allow estimation of the GFR:
Serum creatinine concentration should be measured at initial assessment and then at least annually in all adult patients with:
• Previously diagnosed CKD including: o Identified renal pathology (e.g. polycystic kidney, Biopsy proven GN, reflux nephropathy) o Persistent proteinuria (see page X section X) o Urologically unexplained haematuria
• Conditions associated with a high risk of silent development of obstructive kidney disease: o Bladder voiding dysfunction (outflow obstruction, neurogenic bladder) o Urinary diversion surgery o Urinary stone disease (>one episode/year)
• Conditions associated with a high risk of silent development of parenchymal kidney disease: o Hypertension, diabetes mellitus, heart failure, o Atherosclerotic coronary, cerebral, or peripheral vascular disease
• Conditions requiring long-term treatment with potentially nephrotoxic drugs o e.g ACEIs, ARBs, NSAIDs, Lithium, Mesalazine, Cyclosporin, Tacrolimus
• Multi-system diseases that may involve the kidney o e.g. systemic lupus erythematosus (SLE), vasculitis, myeloma, rheumatoid arthritis.
3.
Testing for urinary protein
Dipstick urinalysis for protein should be undertaken:
• (patients with diabetes mellitus should also have annual testing for albumin:creatinine ratio to exclude 'microalbuminuria' if the dipstick urinalysis for protein is negative)
• As part of routine monitoring for patients receiving nephrotoxic agents eg gold, penicillamine, according to the recommendations in the British National Formulary.
4.
Confirmation of proteinuria
There is no need to perform 24 hr urine collections for quantification of proteinuria (Level 3 DA)
If protein dipstick test is positive (≥1+) the following should be undertaken
• MSU for culture to exclude urinary tract infection (UTI).
• Laboratory confirmation of proteinuria, (Level 3DA) preferably on early morning urine (EMU) sample, to exclude postural proteinuria 
DA
5.
Haematuria
Routine screening for haematuria is not recommended.
• Dipstick urinalysis for blood is the test of choice (Level 3DA) for • confirmation of macroscopic haematuria • detection of microscopic haematuria.
Infection, trauma, and menstruation should t be excluded first. There is no need for microscopy of an MSU sample to detect or confirm haematuria.
• Dipstick urinalysis for blood is indicated as part of initial assessment of patients with • Newly found increased serum creatinine concentration/ reduced GFR • Newly discovered proteinuria • Suspected multi-system disease with possible renal involvement
B. Interpretation of tests / Initial management
Level of evidence 6
Recognition of acute renal failure (ARF)
ARF is characterised by rapid deterioration of renal function over a period of hours or days ARF should be suspected in the context of an acute illness in the presence of:
• A 50% rise in serum creatinine concentration • A fall in estimated GFR of >25% (if baseline unknown assume 75 ml/min/1.73m
2 ) but GFR must be interpreted with caution as formulae rely on a stable creatinine concentration (Level 3 DA)
• Oliguria (urinary output <0.5 ml/kg/hr) Because it requires emergency treatment, all patients with newly detected abnormal renal function should be assumed to have ARF until proven otherwise, although the majority will turn out to have CKD • Review of all previous measurements of serum creatinine o to estimate GFR and assess rate of deterioration.
• Review of medication, particularly o recent additions (e.g. diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), or any drug capable of causing interstitial nephritis eg penicillins, cephalosporins, mesalazine, diuretics)
• Urinalysis: (see page X) o haematuria and proteinuria suggest glomerulonephritis, which may progress rapidly
• Clinical assessment, o eg. looking for sepsis, heart failure, hypovolaemia, palpable bladder.
• Repeat serum creatinine measurement within 5 days o to exclude rapid progression.
• Check criteria for referral (see Table 4 and Box 2) o if not indicated ensure entry into a chronic disease management programme.
8
Management of haematuria should include:
• Check serum creatinine concentration in all patients o refer to nephrologist if GFR < 60 mL/min/1.73 m 2 .
• Check for proteinuria in all patients.
If GFR normal:
Macroscopic haematuria, with or without proteinuria:
• fast track urology referral; refer to nephrology if initial investigations negative.
Microscopic haematuria (dipstick or laboratory microscopy) without dipstick proteinuria:
• Age >50 yrs: refer to urology • Age <50 yrs, or >50 yrs after exclusion of urological cancer: treat as CKD (includes measurement of serum creatinine concentration, annual repeat if initially normal)
Microscopic haematuria with urine protein:creatinine ratio > 45 mg/mmol • refer to nephrology.
There is no need for laboratory confirmation of dipstick positive haematuria. Level 3 DA
3DA
9
Proteinuria: If found, management should include
• Quantification of proteinuria (see section A4), test for haematuria, estimate GFR. o Urine PCR > 100 mg/mmol -refer to Nephrologist irrespective of GFR.
Diabetes Mellitus (DM) and 'microalbuminuria' or proteinuria
• Urinary albumin/creatinine ratio should be measured using a laboratory method if dipstick protein negative (see section 4) preferably on an EMU, but not during acute illness, intercurrent infection or menstruation.
• Persistent urinary albumin/creatinine ratios of ≥2.5 mg/mmol (male) or ≥3.5 mg/mmol(female) on 2-3 occasions are consistent with micro-albuminuria
Manage patients with DM (Type I or II) and microalbuminuria or proteinuria as follows:
• Achieve good glycaemic control (HbA1c 6.5-7.5%). Level 1
• Prescription of an ACEI (or ARB in the presence of a firm contraindication to ACEI), titrated to full dose, irrespective of initial blood pressure Level 1
• Control of hypertension if necessary: Addition of other antihypertensive drugs in combination to reach the blood pressure goal. (Level 1)
• Measurement at least once a year of • urine albumin:creatinine ratio (or PCR)
• serum creatinine concentration (for estimated GFR).
• Referral to diabetes team for review.
• Referral to a nephrologist • as for patients without diabetes.
• Co-ordination of care between the primary care team and specialist teams (including nephrology, ophthalmology, cardiology, and vascular surgery) at all stages of CKD including stage 5. 
Investigation for atherosclerotic renal artery stenosis
Patients should be referred for further investigation for atherosclerotic renal artery stenosis (ARAS), with a view to intervention, in the following situations:
• Refractory hypertension (ie BP > 150/90 mm Hg despite 3 anti-hypertensive agents). Level 3 DA
• Recurrent episodes of pulmonary oedema despite normal left ventricular function on echocardiography (so-called "flash pulmonary oedema", usually associated with hypertension).
Level 3 DA
• Rising serum creatinine concentration (rise of >=20% or fall of GFR of >15%) o over 12 months with a high clinical suspicion of widespread atherosclerosis. o or during the first 2 months after initiation of ACEI or ARB treatment (Level 3DA)
• Unexplained hypokalaemia with hypertension. • Regular measurements of kidney function and other laboratory tests depending on the severity of kidney impairment (see Table 3 ).
• General health advice as appropriate on: o smoking cessation.  if urine PCR >100 mg/mmol  in diabetic patients with micro-albuminuria (see sections 4 and 10) Serum creatinine and potassium should be checked
• before starting medication • two weeks after starting, and after subsequent increases in dose.
If Creatinine increase of >20% or fall in GFR of >15%
• Repeat creatinine, check potassium, and refer for specialist opinion on whether to stop treatment or to investigate for renal artery stenosis.
• Additional management for CKD stage 3 should include:
• Annual measurement of Hb, potassium, calcium and phosphate
• If Hb <11 and other causes excluded:
• treat with erythropoiesis stimulating agents to maintain Hb 11-12 g/dl depending on the patient's functional needs. (Level 1)
• Request renal ultrasonography in • patients with lower urinary tract symptoms,
• refractory hypertension • unexpected progressive fall in GFR.
• Immunise against influenza and pneumococcus.
• Review all prescribed medication regularly to ensure appropriate doses • avoid nephrotoxic drugs including NSAIDs wherever possible .
• Check parathyroid hormone (PTH) concentration when Stage 3 first diagnosed.
• If raised check serum 25-hydroxyvitamin D;
• if this is low treat with ergocalciferol or cholecalciferol with calcium supplement (not calcium phosphate).
• Repeat PTH after 3 months and refer if still raised.
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CKD Stages 4-5 additional management 14
Care of all patients with stage 4 or 5 CKD should be discussed formally with a nephrologist once the appropriate investigations are obtained, even if it is not anticipated that RRT will be appropriate.
Exceptions may include:
• patients in whom stage 4 or 5 CKD supervenes as part of another terminal illness • patients with stable function in whom all the appropriate investigations and management interventions have been performed and who have an agreed and understood care pathway • patients in whom further investigation and management is clearly inappropriate Management should be shared with GP and/or other healthcare professionals and should include:
• 3-monthly tests: serum creatinine (for GFR), Hb, calcium, phosphate, bicarbonate, PTH
• dietary assessment
• immunisation against hepatitis B
• investigation and treatment of phosphate retention and hyper-parathyroidism
• correction of acidosis (Level 2)
• information about options for treatment
• timely provision of dialysis access depending on treatment choice (Level 2) Appendix 1.
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